11 Years of Cyanopyrrolidines as DPP-IV Inhibitors

Publisher： Bentham Science Publishers

E-ISSN： 1873-4294|7|6|579-595

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.7, Iss.6, 2007-03, pp. : 579-595

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sixteen-Years of Clinically Relevant Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors for Treatment of Type-2 Diabetes: A Perspective

By  

Current Medicinal Chemistry, Vol. 21, Iss. 35, 2014-01 ,pp. : 4013-4045

Bentham Science Publishers

Access to resources Recommend Favorite

DPP-IV inhibitors could be cost-effective for T2DM

By  

Inpharma, Vol. 1, Iss. 1642, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

DPP-IV inhibitors could be cost-effective for T2DM

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 556, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

DPP-IV inhibitors/sitagliptin: First report of spermatogenesis abnormalities: case report

By  

Reactions Weekly, Vol. 1, Iss. 1371, 2011-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Computational Identification of Inhibitors Against DPP-IV for Checking Type-2 Diabetes

By  

Letters in Drug Design & Discovery, Vol. 14, Iss. 1, 2017-01 ,pp. : 66-73

Bentham Science Publishers

Access to resources Recommend Favorite